These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38501667)

  • 1. Outcomes After Fecal Microbiota Transplantation in Combination With Bezlotoxumab for Inflammatory Bowel Disease and Recurrent Clostridioides difficile Infection.
    Allegretti JR; Axelrad J; Dalal RS; Kelly CR; Grinspan A; Fischer M
    Am J Gastroenterol; 2024 Jul; 119(7):1433-1436. PubMed ID: 38501667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection in patients with inflammatory bowel disease.
    You JHS; Jiang X; Lee WH; Chan PKS; Ng SC
    J Gastroenterol Hepatol; 2020 Sep; 35(9):1515-1523. PubMed ID: 32017248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile).
    Minkoff NZ; Aslam S; Medina M; Tanner-Smith EE; Zackular JP; Acra S; Nicholson MR; Imdad A
    Cochrane Database Syst Rev; 2023 Apr; 4(4):CD013871. PubMed ID: 37096495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing the efficacy and safety of faecal microbiota transplantation with bezlotoxumab in reducing the risk of recurrent
    Alhifany AA; Almutairi AR; Almangour TA; Shahbar AN; Abraham I; Alessa M; Alnezary FS; Cheema E
    BMJ Open; 2019 Nov; 9(11):e031145. PubMed ID: 31699731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fecal microbiota transplantation for recurrent C. difficile infection in patients with inflammatory bowel disease: experience of a large-volume European FMT center.
    Ianiro G; Bibbò S; Porcari S; Settanni CR; Giambò F; Curta AR; Quaranta G; Scaldaferri F; Masucci L; Sanguinetti M; Gasbarrini A; Cammarota G
    Gut Microbes; 2021; 13(1):1994834. PubMed ID: 34709989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of recurrent Clostridioides difficile infection: A systematic review of randomized controlled trials.
    Madoff SE; Urquiaga M; Alonso CD; Kelly CP
    Anaerobe; 2020 Feb; 61():102098. PubMed ID: 31493500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microbial Engraftment and Efficacy of Fecal Microbiota Transplant for Clostridium Difficile in Patients With and Without Inflammatory Bowel Disease.
    Hirten RP; Grinspan A; Fu SC; Luo Y; Suarez-Farinas M; Rowland J; Contijoch EJ; Mogno I; Yang N; Luong T; Labrias PR; Peter I; Cho JH; Sands BE; Colombel JF; Faith JJ; Clemente JC
    Inflamm Bowel Dis; 2019 May; 25(6):969-979. PubMed ID: 30852592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic Association Reveals Protection against Recurrence of
    Shen J; Mehrotra DV; Dorr MB; Zeng Z; Li J; Xu X; Nickle D; Holzinger ER; Chhibber A; Wilcox MH; Blanchard RL; Shaw PM
    mSphere; 2020 May; 5(3):. PubMed ID: 32376702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fecal microbiota transplantation for recurrent Clostridioides difficile infection in patients with concurrent ulcerative colitis.
    Porcari S; Severino A; Rondinella D; Bibbò S; Quaranta G; Masucci L; Maida M; Scaldaferri F; Sanguinetti M; Gasbarrini A; Cammarota G; Ianiro G
    J Autoimmun; 2023 Dec; 141():103033. PubMed ID: 37085337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of C. difficile infection-related outcomes in European participants in the bezlotoxumab MODIFY I and II trials.
    Bouza E; Cornely OA; Ramos-Martinez A; Plesniak R; Ellison MC; Hanson ME; Dorr MB
    Eur J Clin Microbiol Infect Dis; 2020 Oct; 39(10):1933-1939. PubMed ID: 32504314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence.
    Gerding DN; Kelly CP; Rahav G; Lee C; Dubberke ER; Kumar PN; Yacyshyn B; Kao D; Eves K; Ellison MC; Hanson ME; Guris D; Dorr MB
    Clin Infect Dis; 2018 Aug; 67(5):649-656. PubMed ID: 29538686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and Safety of Colonic and Capsule Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection.
    Vaughn BP; Fischer M; Kelly CR; Allegretti JR; Graiziger C; Thomas J; McClure E; Kabage AJ; Khoruts A
    Clin Gastroenterol Hepatol; 2023 May; 21(5):1330-1337.e2. PubMed ID: 36126907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A time-to-event analysis of the exposure-response relationship for bezlotoxumab concentrations and CDI recurrence.
    Yee KL; Kleijn HJ; Zajic S; Dorr MB; Wrishko RE
    J Pharmacokinet Pharmacodyn; 2020 Apr; 47(2):121-130. PubMed ID: 32048107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fecal microbiota transplantation for recurrent C. difficile infection in patients with inflammatory bowel disease: A systematic review and meta-analysis.
    Porcari S; Baunwall SMD; Occhionero AS; Ingrosso MR; Ford AC; Hvas CL; Gasbarrini A; Cammarota G; Ianiro G
    J Autoimmun; 2023 Dec; 141():103036. PubMed ID: 37098448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in microbial ecology after fecal microbiota transplantation for recurrent C. difficile infection affected by underlying inflammatory bowel disease.
    Khanna S; Vazquez-Baeza Y; González A; Weiss S; Schmidt B; Muñiz-Pedrogo DA; Rainey JF; Kammer P; Nelson H; Sadowsky M; Khoruts A; Farrugia SL; Knight R; Pardi DS; Kashyap PC
    Microbiome; 2017 May; 5(1):55. PubMed ID: 28506317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bezlotoxumab use as adjunctive therapy with the third fecal microbiota transplant in refractory recurrent Clostridium difficile colitis; a case report and concise literature review.
    Kaako A; Al-Amer M; Abdeen Y
    Anaerobe; 2019 Feb; 55():112-116. PubMed ID: 30521856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term durability and safety of fecal microbiota transplantation for recurrent or refractory Clostridioides difficile infection with or without antibiotic exposure.
    Lee CH; Chai J; Hammond K; Jeon SR; Patel Y; Goldeh C; Kim P
    Eur J Clin Microbiol Infect Dis; 2019 Sep; 38(9):1731-1735. PubMed ID: 31165961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A network meta-analysis of randomized controlled trials exploring the role of fecal microbiota transplantation in recurrent
    Rokkas T; Gisbert JP; Gasbarrini A; Hold GL; Tilg H; Malfertheiner P; Megraud F; O'Morain C
    United European Gastroenterol J; 2019 Oct; 7(8):1051-1063. PubMed ID: 31662862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Fecal Microbiota Transplantation on Recurrence in Multiply Recurrent Clostridium difficile Infection: A Randomized Trial.
    Kelly CR; Khoruts A; Staley C; Sadowsky MJ; Abd M; Alani M; Bakow B; Curran P; McKenney J; Tisch A; Reinert SE; Machan JT; Brandt LJ
    Ann Intern Med; 2016 Nov; 165(9):609-616. PubMed ID: 27547925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammatory Bowel Disease Affects the Outcome of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection.
    Khoruts A; Rank KM; Newman KM; Viskocil K; Vaughn BP; Hamilton MJ; Sadowsky MJ
    Clin Gastroenterol Hepatol; 2016 Oct; 14(10):1433-8. PubMed ID: 26905904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.